Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Dépistage du cancer de la prostate chez les patients âgés (PLCO Screening Trial)

10 novembre 2026 mis à jour par: National Cancer Institute (NCI)

Essai de dépistage du cancer de la prostate, du poumon, colorectal et de l'ovaire (PLCO)

This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for prostate cancer.

Aperçu de l'étude

Description détaillée

PRIMARY OBJECTIVES:

I. To determine whether screening with digital rectal examination (DRE) plus serum prostate-specific antigen (PSA) can reduce mortality from prostate cancer in men aged 55-74 at entry.

SECONDARY OBJECTIVES:

I. To assess screening variables, other than mortality, for each of the interventions including sensitivity, specificity, and positive predictive value.

II. To assess the incidence, stage, and survival of cancer cases. III. To investigate the mortality predictive value of biologic and/or prognostic characterizations of tumor tissue as intermediate endpoints.

IV. To conduct biomolecular and genetic research into factors associated with cancer carcinogenesis and promotion, as well as the early detection of these factors.

OUTLINE: Participants in the overall PLCO study are stratified by screening center, gender, and age (55-59 vs 60-64 vs 65-69 vs 70-74). Participants are randomized to 1 of 2 arms (control vs screening).

ARM I (Control): Participants receive standard medical care. Participants complete a Diet History Questionnaire (DHQ) at baseline.

ARM II (Prostate Screening): Participants undergo blood sample collection for PSA analysis at baseline and annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo a DRE at baseline and annually for 3 years. A scheduling and tracking procedure is implemented to ensure regular attendance at repeat screens for participants screened negative or for those who are designated suspicious or positive at screening but for whom subsequent diagnostic procedures do not reveal prostate cancer (follow-up diagnostic procedures are through their own medical care environment). Participants diagnosed with prostate cancer via a screening test are referred for treatment in accordance with current accepted practice for appropriate stage of disease, patient age, and medical condition; a procedure is provided for contact with qualified medical personnel to insure appropriate therapy.

Participants complete a Dietary Questionnaire (DQX) at baseline and DHQ at year 3. An Annual Study Update (ADU) (previously referred to as the Periodic Survey of Health [PSH] questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident prostate cancers as all deaths that occur among both screened and control subjects during the trial.

After completion of screening, participants are followed up for at least 13 years.

Type d'étude

Interventionnel

Inscription (Réel)

76685

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Maryland
      • Bethesda, Maryland, États-Unis, 20892
        • National Institutes of Health Clinical Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

55 ans à 74 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Homme

La description

Exclusion Criteria:

  • Men who at the time of randomization are less than 55 or greater than or equal to 75 years of age

  • Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer

  • Individuals with known prior cancer of the colon, rectum, lung, prostate

    • This includes primary or metastatic PLCO cancers
  • Individuals with previous surgical removal of the entire colon, one lung, or the entire prostate

  • Individuals who are participating in another cancer screening or cancer primary prevention trial

  • Males who have taken Proscar/Propecia/finasteride in the past 6 months

    • NOTE: Individuals who are already enrolled in the trial when their physician prescribes finasteride are not prevented from taking this medication. As a result, these participants will continue to be screened and followed just as those participants who are not on finasteride.
    • NOTE: Men who are taking Tamoxifen are not excluded from any part of the PLCO Screening Trial.
  • Individuals who are unwilling or unable to sign the informed consent form

  • Males who have had more than one PSA blood test in the past three years

  • Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Dépistage
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Aucune intervention: Control

Participants receive standard medical care. Participants complete a DHQ at baseline.

Comparateur actif: Prostate Screening

Participants undergo blood sample collection for PSA analysis at baseline and annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo a DRE at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident prostate cancers as all deaths that occur among both screened and control subjects during the trial.

Correlative studies

Undergo questionnaire assessments

Undergo DRE

Autres noms:
  • Examen
  • Évaluation médicale
  • Examen médical
  • Inspection médicale
  • Évaluation de la santé
  • Évaluation de l'état de santé
  • Examen de santé

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Prostate Cancer Deaths
Délai: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.
Prostate Cancer Death Rates
Délai: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test
Délai: One year from screening examination

Number of positive screens with complications

One year from screening examination
Deaths From All Causes
Délai: Events through 13 years of follow-up or through December 31, 2009.

Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm.

Events through 13 years of follow-up or through December 31, 2009.
Death Rates From All Causes
Délai: Events through 13 years of follow-up or through December 31, 2009.

Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study.

Events through 13 years of follow-up or through December 31, 2009.
Prostate Cancer Incidence
Délai: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.
Prostate Cancer Incidence Rates
Délai: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.
T0 (Baseline) PSA Screening Results
Délai: T0 (at study entry)

Prostate-Specific Antigen (PSA) result.

T0 (at study entry)
T0 (Baseline) DRE Screening Results
Délai: T0 (at study entry)

Digital Rectal Examination (DRE) result.

T0 (at study entry)
T1 PSA Screening Results
Délai: T1 (one year after entry)

Prostate-Specific Antigen (PSA) result.

T1 (one year after entry)
T1 DRE Screening Results
Délai: T1 (one year after entry)

Digital Rectal Examination (DRE) result.

T1 (one year after entry)
T2 PSA Screening Results
Délai: T2 (two years after entry)

Prostate-Specific Antigen (PSA) result.

T2 (two years after entry)
T2 DRE Screening Results
Délai: T2 (two years after entry)

Digital Rectal Examination (DRE) results

T2 (two years after entry)
T3 PSA Screening Results
Délai: T3 (three years after entry)

Prostate-Specific Antigen (PSA) result

T3 (three years after entry)
T3 DRE Screening Results
Délai: T3 (three years after entry)

Digital Rectal examination (DRE) result

T3 (three years after entry)
T4 PSA Screening Result
Délai: T4 (four years after entry)

Prostate-Specific Antigen (PSA) result

T4 (four years after entry)
T5 PSA Screening Results
Délai: T5 (five years after entry)

Prostate-Specific Antigen (PSA) result.

T5 (five years after entry)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Christine D Berg, National Cancer Institute (NCI)

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

16 novembre 1993

Achèvement primaire (Réel)

21 mai 2012

Achèvement de l'étude (Estimé)

30 juin 2027

Dates d'inscription aux études

Première soumission

1 novembre 1999

Première soumission répondant aux critères de contrôle qualité

25 mars 2004

Première publication (Estimé)

26 mars 2004

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 juillet 2026

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner